JPMorgan Maintains ‘Overweight’ Rating on Eli Lilly and Company (LLY) With $1,100 PT

Eli Lilly and Company (NYSE:LLY) is included in our list of the 11 Best Rebound Stocks to Buy According to Hedge Funds.

JPMorgan Maintains ‘Overweight’ Rating on Eli Lilly and Company (LLY) With $1,100 PT

An operating theatre with medical personnel and a patient in pre-op for a Neuro-Spinal Scaffold Implant.

On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and Company (NYSE:LLY) with a $1,100 price target. This target boost follows the company’s Q2 results. While investor sentiment weakened over Phase 3 trial data for Orforglipron, which recorded an efficacy of 1-2 percentage points, roughly 2-4 pounds below expectations, the investment firm believes it has minimal long-term impact.

Furthermore, JPMorgan expressed confidence in Orforglipron, the company’s oral obesity drug candidate, believing that the drug’s prospects remain solid. Looking ahead, the investment firm backs its optimism with Eli Lilly and Company (NYSE:LLY)’s significant ramp-up, which is expected in the second half of 2026 and beyond. Thus, the company remains well-positioned to capture demand in the fast-growing obesity market.

Eli Lilly and Company (NYSE:LLY) specializes in treatments for diabetes, obesity, and other health conditions. It is included in our list of the Best Rebound Stocks To Buy.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best AI Stocks to Buy Under $3 and Bill Ackman Stock Portfolio: Top 10 Stock Picks.

Disclosure: None.